Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1457-1459

  Hoos, Axel ^a,c   Janetzki, Sylvia ^b,c   Britten, Cedrik M ^d,e  

^a GLAXOSMITHKLINE   (United States)

^b Zellnet Consulting   (United States)

^c Cancer Immunotherapy Consortium (CIC)   (United States)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e Association for Cancer Immunotherapy (CIMT)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER IMMUNOTHERAPY; CONSENSUS; EDITORIAL; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; T LYMPHOCYTE; TREATMENT RESPONSE; VOLUNTARY REPORTING;

EID: 84886945201     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22308     Document Type: Editorial

References (12)

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
3. Hoos A, Eggermont AMM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102:1388-97; PMID:20826737; http://dx.doi.org/10.1093/jnci/djq310.
4. Hoos A, Britten CM, Huber C, O'Donnell-Tormey J. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol 2011; 29:867-70; PMID:21997622; http://dx.doi.org/10.1038/nbt.2000.
5. van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, et al. Harmonization of immune biomarker assays for clinical studies. Sci Transl Med 2011; 3:08ps44; PMID:22072636; http://dx.doi.org/10.1126/scitranslmed.3002785.
6. Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Toward the harmonization of immune monitoring in clinical trials: quo vadis?. Cancer Immunol Immunother 2008; 57:285-8; PMID:17721782; http://dx.doi.org/10.1007/s00262-007-0379-z.
7. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJM, et al. "MIATA"-minimal information about T cell assays. Immunity 2009; 31:527-8; PMID:19833080; http://dx.doi.org/10.1016/j.immuni.2009.09.007.
8. Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, et al. T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. [Letter]. Immunity 2012; 37:1-2; PMID:22840835; http://dx.doi.org/10.1016/j.immuni.2012.07.010.
9. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001; 29:365-71; PMID:11726920; http://dx.doi.org/10.1038/ng1201-365.
10. Taylor CF, Field D, Sansone S-A, Aerts J, Apweiler R, Ashburner M, et al. Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol 2008; 26:889-96; PMID:18688244; http://dx.doi.org/10.1038/nbt.1411.
11. Britten CM, Janetzki S, Van der Burg SH, Huber C, Kalos M, Levitsky HI, et al. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother 2010; In press; PMID:21080166.
12. Hoos A, Britten C. The immuno-oncology framework: Enabling a new era of cancer therapy. Oncoimmunology 2012; 1:334-9; PMID:22737609; http://dx.doi.org/10.4161/onci.19268.